EVOTEC SE (EVT.DE) Stock Fundamental Analysis

FRA:EVT • DE0005664809

5.686 EUR
-0.17 (-2.94%)
Last: Mar 2, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EVT. EVT was compared to 18 industry peers in the Life Sciences Tools & Services industry. EVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EVT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • EVT had negative earnings in the past year.
  • In the past year EVT had a positive cash flow from operations.
  • In multiple years EVT reported negative net income over the last 5 years.
  • EVT had a positive operating cash flow in each of the past 5 years.
EVT.DE Yearly Net Income VS EBIT VS OCF VS FCFEVT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -8.97%, EVT is doing worse than 88.89% of the companies in the same industry.
  • The Return On Equity of EVT (-19.87%) is worse than 83.33% of its industry peers.
Industry RankSector Rank
ROA -8.97%
ROE -19.87%
ROIC N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
EVT.DE Yearly ROA, ROE, ROICEVT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

  • EVT has a Gross Margin of 10.82%. This is amonst the worse of the industry: EVT underperforms 88.89% of its industry peers.
  • EVT's Gross Margin has declined in the last couple of years.
  • EVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
EVT.DE Yearly Profit, Operating, Gross MarginsEVT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • EVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • EVT has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for EVT has been increased compared to 5 years ago.
  • Compared to 1 year ago, EVT has an improved debt to assets ratio.
EVT.DE Yearly Shares OutstandingEVT.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
EVT.DE Yearly Total Debt VS Total AssetsEVT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of 1.19, we must say that EVT is in the distress zone and has some risk of bankruptcy.
  • EVT has a worse Altman-Z score (1.19) than 72.22% of its industry peers.
  • A Debt/Equity ratio of 0.48 indicates that EVT is not too dependend on debt financing.
  • EVT has a Debt to Equity ratio of 0.48. This is in the better half of the industry: EVT outperforms 72.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z 1.19
ROIC/WACCN/A
WACC7.81%
EVT.DE Yearly LT Debt VS Equity VS FCFEVT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • EVT has a Current Ratio of 2.12. This indicates that EVT is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of EVT (2.12) is better than 88.89% of its industry peers.
  • A Quick Ratio of 2.03 indicates that EVT has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 2.03, EVT belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 2.03
EVT.DE Yearly Current Assets VS Current LiabilitesEVT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for EVT have decreased strongly by -136.17% in the last year.
  • The Revenue has decreased by -2.67% in the past year.
  • Measured over the past years, EVT shows a quite strong growth in Revenue. The Revenue has been growing by 12.29% on average per year.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%

3.2 Future

  • EVT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.36% yearly.
  • The Revenue is expected to grow by 4.91% on average over the next years.
EPS Next Y50.73%
EPS Next 2Y35.51%
EPS Next 3Y27.78%
EPS Next 5Y18.36%
Revenue Next Year-2.87%
Revenue Next 2Y2.01%
Revenue Next 3Y4.83%
Revenue Next 5Y4.91%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EVT.DE Yearly Revenue VS EstimatesEVT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
EVT.DE Yearly EPS VS EstimatesEVT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • EVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVT.DE Price Earnings VS Forward Price EarningsEVT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 -30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EVT indicates a rather expensive valuation: EVT more expensive than 83.33% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1223.54
EVT.DE Per share dataEVT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • EVT's earnings are expected to grow with 27.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.51%
EPS Next 3Y27.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for EVT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EVOTEC SE

FRA:EVT (3/2/2026, 7:00:00 PM)

5.686

-0.17 (-2.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05
Earnings (Next)N/A
Inst Owners50.94%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.02B
Revenue(TTM)756.33M
Net Income(TTM)-158.98M
Analysts78.46
Price Target9.07 (59.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.59%
Min EPS beat(2)-21.86%
Max EPS beat(2)-3.31%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.97%
Min Revenue beat(2)-9.17%
Max Revenue beat(2)-4.77%
Revenue beat(4)0
Avg Revenue beat(4)-4.99%
Min Revenue beat(4)-9.17%
Max Revenue beat(4)-0.93%
Revenue beat(8)1
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)1.12%
Revenue beat(16)7
Avg Revenue beat(16)2.95%
PT rev (1m)2.56%
PT rev (3m)-1.76%
EPS NQ rev (1m)47.37%
EPS NQ rev (3m)47.37%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.34%
Revenue NQ rev (1m)1.79%
Revenue NQ rev (3m)1.79%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)-0.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.67
P/FCF N/A
P/OCF 1432.01
P/B 2.52
P/tB 4.04
EV/EBITDA 1223.54
EPS(TTM)-1.11
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)0
OCFY0.07%
SpS2.13
BVpS2.25
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.97%
ROE -19.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.82%
FCFM N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA 209.82
Cap/Depr 90.72%
Cap/Sales 12.19%
Interest Coverage N/A
Cash Conversion 76.3%
Profit Quality N/A
Current Ratio 2.12
Quick Ratio 2.03
Altman-Z 1.19
F-Score4
WACC7.81%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y50.73%
EPS Next 2Y35.51%
EPS Next 3Y27.78%
EPS Next 5Y18.36%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%
Revenue Next Year-2.87%
Revenue Next 2Y2.01%
Revenue Next 3Y4.83%
Revenue Next 5Y4.91%
EBIT growth 1Y-6.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.95%
EBIT Next 3Y47.8%
EBIT Next 5Y32.84%
FCF growth 1Y52.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y107.69%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%

EVOTEC SE / EVT.DE FAQ

Can you provide the ChartMill fundamental rating for EVOTEC SE?

ChartMill assigns a fundamental rating of 3 / 10 to EVT.DE.


What is the valuation status for EVT stock?

ChartMill assigns a valuation rating of 1 / 10 to EVOTEC SE (EVT.DE). This can be considered as Overvalued.


How profitable is EVOTEC SE (EVT.DE) stock?

EVOTEC SE (EVT.DE) has a profitability rating of 1 / 10.


What is the financial health of EVOTEC SE (EVT.DE) stock?

The financial health rating of EVOTEC SE (EVT.DE) is 5 / 10.


Can you provide the expected EPS growth for EVT stock?

The Earnings per Share (EPS) of EVOTEC SE (EVT.DE) is expected to grow by 50.73% in the next year.